US EditionPublished • loading... • Updated
Ardena Finalizes Sale of Sweden Drug Substance Site to Nanologica – EUROP INFO
Summary by EURO-NEWS
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Ardena Finalizes Sale of Sweden Drug Substance Site to Nanologica – EUROP INFO
Ardena has officially completed the divestment of its drug substance manufacturing site in Sweden to Nanologica, marking a significant strategic move in the contract pharmaceutical sector. The transaction reinforces Nanologica’s position in advanced drug development and manufacturing, while allowing Ardena to streamline its operations and focus on its core competencies. This deal highlights ongoing consolidation trends within the pharmaceutical …
Ardena completes divestment of its Södertälje drug substance site in Sweden to Nanologica
Ardena, a specialist CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, has announced that it has completed the divestment of its drug substance (API) site in Södertälje, Sweden, to Nanologica.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
